TY - JOUR
T1 - Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study
AU - Shrotri, Madhumita
AU - Fragaszy, Ellen
AU - Nguyen, Vincent
AU - Navaratnam, Annalan M.D.
AU - Geismar, Cyril
AU - Beale, Sarah
AU - Kovar, Jana
AU - Byrne, Thomas E.
AU - Fong, Wing Lam Erica
AU - Patel, Parth
AU - Aryee, Anna
AU - Braithwaite, Isobel
AU - Johnson, Anne M.
AU - Rodger, Alison
AU - Hayward, Andrew C.
AU - Aldridge, Robert W.
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Vaccination constitutes the best long-term solution against Coronavirus Disease-2019; however, vaccine-derived immunity may not protect all groups equally, and the durability of protective antibodies may be short. We evaluate Spike-antibody responses following BNT162b2 or ChAdOx1-S vaccination amongst SARS-CoV2-naive adults across England and Wales enrolled in a prospective cohort study (Virus Watch). Here we show BNT162b2 recipients achieved higher peak antibody levels after two doses; however, both groups experience substantial antibody waning over time. In 8356 individuals submitting a sample ≥28 days after Dose 2, we observe significantly reduced Spike-antibody levels following two doses amongst individuals reporting conditions and therapies that cause immunosuppression. After adjusting for these, several common chronic conditions also appear to attenuate the antibody response. These findings suggest the need to continue prioritising vulnerable groups, who have been vaccinated earliest and have the most attenuated antibody responses, for future boosters.
AB - Vaccination constitutes the best long-term solution against Coronavirus Disease-2019; however, vaccine-derived immunity may not protect all groups equally, and the durability of protective antibodies may be short. We evaluate Spike-antibody responses following BNT162b2 or ChAdOx1-S vaccination amongst SARS-CoV2-naive adults across England and Wales enrolled in a prospective cohort study (Virus Watch). Here we show BNT162b2 recipients achieved higher peak antibody levels after two doses; however, both groups experience substantial antibody waning over time. In 8356 individuals submitting a sample ≥28 days after Dose 2, we observe significantly reduced Spike-antibody levels following two doses amongst individuals reporting conditions and therapies that cause immunosuppression. After adjusting for these, several common chronic conditions also appear to attenuate the antibody response. These findings suggest the need to continue prioritising vulnerable groups, who have been vaccinated earliest and have the most attenuated antibody responses, for future boosters.
UR - https://www.scopus.com/pages/publications/85139121767
U2 - 10.1038/s41467-022-33550-z
DO - 10.1038/s41467-022-33550-z
M3 - Article
C2 - 36184633
AN - SCOPUS:85139121767
SN - 2041-1723
VL - 13
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 5780
ER -
